Nail Psoriasis and Quality-of-Life Measurement in Clinical Trials: Call for the Use of Nail-Specific Instruments

Abstract

Nail involvement is frequent in people with psoriasis. It can considerably impair health-related quality of life (HRQoL) beyond the impairments due to other psoriasis symptoms, for example, because patients feel ashamed of visible nail defects or because of the functional impairment in manual activities and walking. In clinical trials on nail psoriasis, it is therefore crucial to assess whether the treatment reduces HRQoL impairments that are specific to nail psoriasis. For this purpose, two validated patient questionnaires are available, the Nail Psoriasis Quality of Life Scale (NPQ10) and the Nail Assessment in Psoriasis and Psoriatic Arthritis-Quality of Life (NAPPA-QOL). The ten-item NPQ10 has the advantage of being short and thus quick to administer. The 20-item NAPPA-QOL, in contrast, assesses the different dimensions of HRQoL which is considered a multi-dimensional construct. Yet most randomized controlled trials on nail psoriasis do not evaluate HRQoL improvement. If they do, a number of different instruments are used, most of which are not nail specific. This makes comparison of trial outcomes difficult. Harmonizing the measurement of HRQoL in future clinical trials on nail psoriasis would improve comparability across studies and would also enhance the reliability of meta-analyses. Key PointsPatients with nail psoriasis have specific quality-of-life impairments as compared to patients with psoriasis in general.Quality-of-life impairments that stem specifically from nail involvement in psoriasis should be measured with nail psoriasis-specific and validated questionnaires.In order to enable comparisons between clinical studies, harmonization of measurement instruments to be used across trials is needed.

Real‐world effectiveness and safety of tildrakizumab in long‐term treatment of plaque psoriasis: Results from the non‐interventional, prospective, multicentre study TILOT

“…This study also supports the real‐world performance of TIL in reducing subjective symptoms of disease such as itch and improving psoriasis in visible areas such as the scalp and nails. 39 , 40 Longer‐term data from TILOT and other studies will deepen the understanding of the real‐world effectiveness and impact on the quality of life of TIL for the treatment of plaque psoriasis.…”

Sustained Resolution of Nail Psoriasis Through 5 Years with Ixekizumab: A Post-Hoc analysis from UNCOVER-3

“…Nail psoriasis (NP) is a chronic condition present in up to half of patients with psoriasis and is highly visible, interferes with manual dexterity, and can cause unpleasant sensations, such as pain ( 1 ). For these reasons, quality of life impairment among affected patients is often considerably more severe compared with involvement of other anatomical regions ( 2 ). Moreover, presence of nail changes is not only indicative of more severe psoriasis, but is also a predictor of the future development of psoriatic arthritis, thus supporting the need for early diagnosis and effective targeted treatment ( 3 ).…”